Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...
Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...
Moreover, this combination is active against P53-negative and FLT3-ITD-positive cell lines. Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the ...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT ... KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in ...
Midostaurin, which targets the FLT3 receptor (WT and/or mutant), was ... Preclinical studies with cancer cells derived from AML patients treated with midostaurin ex vivo demonstrated that ...
Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and ... of advanced renal cell carcinoma and unresectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results